1 June 2008 in British Journal of Pharmacology
Background and purpose: 5‐HT is a vasoconstrictor exhibiting enhanced effects in systemic arteries from subjects with cardiovascular disease. The effect of endogenous 5‐HT on arteries is controversial, because the concentration of free circulating 5‐HT is low and a 5‐hydroxytryptaminergic system has not been identified in peripheral arteries. We hypothesized that a local 5‐hydroxytryptaminergic system (including 5‐HT synthesis, metabolism, uptake and release) with physiological function exists in peripheral arteries.Experimental approach: The presence of key components of a 5‐hydroxytryptaminergic system in rat aorta and superior mesenteric artery was examined using western blot analyses, immunohistochemistry and immunocytochemistry. The function of the rate‐limiting enzyme in 5‐HT biosynthesis, tryptophan hydroxylase (TPH), and 5‐HT transporter was tested by measuring enzyme activity and 5‐HT uptake, respectively. Isometric contraction of arterial strips was used to demonstrate the function of released endogenous 5‐HT in arterial tissues.Key results: mRNA for TPH‐1 was present in arteries, with low levels of TPH protein and TPH activity. Expression and function of MAO A (5‐HT metabolizing enzyme) was supported by immunohistochemistry, western analyses and the elevation of concentrations of 5‐hydroxyindoleacetic acid (5‐HT metabolite) after exposure to exogenous 5‐HT. The 5‐HT transporter was localized to the plasma membrane of freshly isolated aortic smooth muscle cells. Peripheral arteries actively took up 5‐HT in a time‐dependent and 5‐HT transporter‐dependent manner. The 5‐HT transporter substrate, (+)‐fenfluramine, released endogenous 5‐HT from peripheral arteries, which potentiated noradrenaline‐induced arterial contraction.Conclusions and implications: This study revealed the existence of a local 5‐hydroxytryptaminergic system in peripheral arteries.British Journal of Pharmacology (2008) 154, 663–674; doi:10.1038/bjp.2008.111; published online 14 April 2008
8 May 2023 in JCI Insight
Central conducting lymphatic anomaly (CCLA) due to congenital maldevelopment of the lymphatics can result in debilitating and life-threatening disease with limited treatment options. We identified 4 individuals with CCLA, lymphedema, and microcystic lymphatic malformation due to pathogenic, mosaic variants in KRAS . To determine the functional impact of these variants and identify a targeted therapy for these individuals, we used primary human dermal lymphatic endothelial cells (HDLECs) and zebrafish larvae to model the lymphatic dysplasia. Expression of the p.Gly12Asp and p.Gly13Asp variants in HDLECs in a 2‑dimensional (2D) model and 3D organoid model led to increased ERK phosphorylation, demonstrating these variants activate the RAS/MAPK pathway. Expression of activating KRAS variants in the venous and lymphatic endothelium in zebrafish resulted in lymphatic dysplasia and edema similar to the individuals in the study. Treatment with MEK inhibition significantly reduced the phenotypes in both the organoid and the zebrafish model systems. In conclusion, we present the molecular characterization of the observed lymphatic anomalies due to pathogenic, somatic, activating KRAS variants in humans. Our preclinical studies suggest that MEK inhibition should be studied in future clinical trials for CCLA due to activating KRAS pathogenic variants.
1 September 2013 in Microvascular Research
28 April 2023 in Genetics in Medicine
9 June 2023 in American Journal of Medical Genetics Part C: Seminars in Medical Genetics